Drospirenone / ethinylestradiol, betadex clathrate / L-5-methyltetrahydrofolic acid, calcium salt
Key facts
| Active substance |
|
| Therapeutic area |
Endocrinology-Gynaecology-Fertility-Metabolism
|
| Decision number |
P/130/2009
|
| PIP number |
Drospirenone / ethinylestradiol, betadex clathrate / L-5-methyltetrahydrofolic acid, calcium salt
|
| Pharmaceutical form(s) |
Film-coated tablet
|
| Condition(s) / indication(s) |
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Bayer Schering Pharma AG
E-mail: pediatrics.medical-affairs-europe@bayerhealthcare.com
Country: Germany Phone: +49 3046815333 Fax: +49 3046895333 |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|